UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE TO
(RULE 14D-100)
Tender Offer Statement Under Section 14(d)(1) or 13(e)(1)
of the Securities Exchange Act of 1934
CNL HEALTHCARE PROPERTIES, INC.
(Name of Subject Company)
WEST 4 CAPITAL LP
GRANITE SAPPHIRE MANAGEMENT LIMITED
WEST 4 CAPITAL INVESTMENT ADVISER LIMITED
CAPRICORN FUND MANAGERS LIMITED
(Offerors)
(Names of Filing Persons)
COMMON STOCK, $0.01 PAR VALUE
(Title of Class of Securities)
None or unknown
(CUSIP Number of Class of Securities)
Ronen Capeluto
West 4 Capital LP
c/o Walkers Corporate Limited
2nd Floor, Century Yard
Cricket Square, George Town
P.O. Box 31162
Grand Cayman, KY1-1205
Cayman Islands
+972-54-206-2957
(Name, address and telephone number of person authorized to receive notices and communications on behalf of
filing persons)
with copies to:
Amos W. Barclay
Holland & Hart LLP
1800 Broadway, Suite 300
Boulder, Colorado 80302
(303) 473-2700
| ¨ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. | ||
| Check the appropriate boxes below to designate any transactions to which the statement relates: | |||
| x | third-party tender offer subject to Rule 14d-1. | ||
| ¨ | issuer tender offer subject to Rule 13e-4. | ||
| ¨ | going-private transaction subject to Rule 13e-3. | ||
| ¨ | amendment to Schedule 13D under Rule 13d-2. | ||
| Check the following box if the filing is a final amendment reporting the results of the tender offer: ¨ | |||
| If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon: | |||
| ¨ | Rule 13e-4(i) (Cross-Border Issuer Tender Offer) | ||
| ¨ | Rule 14d-1(d) (Cross-Border Third-Party Tender Offer) | ||
TENDER OFFER
This Tender Offer Statement on Schedule TO relates to the offer (the “Offer”) by West 4 Capital LP (the “Purchaser”) to purchase up to 8,800,000 shares of common stock, par value $0.01 per share (the “Shares”), in CNL Healthcare Properties, Inc. (the “Corporation”), the subject company, at a purchase price equal to $3.29 per Share, upon the terms and subject to the conditions set forth in the Offer to Purchase (the “Offer to Purchase”) dated January 27, 2025 (the “Offer Date”) and the related Assignment Form, copies of which are attached hereto as Exhibits (a)(1) and (a)(2), respectively. Any dividends paid after March 26, 2025, or such other date to which the Offer may be extended (the “Expiration Date”), by the terms of the Offer and as set forth in the Assignment Form, would be assigned by tendering Shareholders to the Purchaser.
Tenders of Shares will include the tender of any and all securities into which the Shares may be converted and any securities distributed with respect to the Shares from and after the Offer Date. The Purchaser is entitled to all proceeds that are paid after the Expiration Date from or as a result of any claim, litigation, class or derivative action brought by or for the benefit of the tendering Shareholders with respect to the transferred Shares, regardless of when the claims asserted and such action accrued.
The Corporation reported approximately 46,183 Shareholders of record as of December 31, 2023, and reported a total of 175,274,045 shares of common stock outstanding as of March 7, 2024, according to its Annual Report on Form 10-K for the fiscal year ended December 31, 2023, and reported a total of 175,274,045 shares of common stock outstanding as of November 7, 2024, according to its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024. The Purchaser and its affiliates currently own 118,453 shares of the Corporation’s common stock, or approximately 0.07% of the common stock outstanding as of November 7, 2024. The 8,800,000 Shares subject to the Offer constitute approximately 5.0% of the outstanding shares of common stock of the Corporation as of November 7, 2024. Consummation of the Offer, if all Shares sought are tendered, would require payment by the Purchaser of up to $28,952,000 in aggregate purchase price, which the Purchaser intends to fund out of its available cash on hand.
The address of the Corporation’s principal executive offices is CNL Center at City Commons, 450 South Orange Avenue, Orlando, Florida 32801, and its phone number is (407) 650-1000.
The information in the Offer to Purchase, including all schedules and annexes thereto, is hereby expressly incorporated herein by reference in response to all the items of this Statement.
Item 12. Exhibits.
| (a)(1) | Offer to Purchase |
| (a)(2) | Assignment Form |
| (a)(3) | Letter to Shareholders |
| (a)(4) | Summary Advertisement |
| (b) - (h) | Not applicable. |
| 107 | Calculation of Filing Fee Table. |
Item 13. Information Required by Schedule 13E-3.
Not applicable.
SIGNATURES
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Dated: January 27, 2025
| West 4 Capital LP | |||
| By: | /s/ Ronen Capeluto | ||
| Ronen Capeluto | |||
| Chief Investment Officer | |||
| Granite Sapphire Management Limited | |||
| By: | /s/ Ronan Guilfoyle | ||
| Ronan Guilfoyle | |||
| Director | |||
| West 4 Capital Investment Adviser Limited | |||
| By: | /s/ Ronen Torem | ||
| Ronen Torem | |||
| Director | |||
| Capricorn Fund Managers Limited | |||
| By: | /s/ Darryl Noik | ||
| Darryl Noik | |||
| Director | |||
